BR112019023014A2 - constructos de lamp aperfeiçoados compreendendo antígenos de câncer - Google Patents
constructos de lamp aperfeiçoados compreendendo antígenos de câncer Download PDFInfo
- Publication number
- BR112019023014A2 BR112019023014A2 BR112019023014-9A BR112019023014A BR112019023014A2 BR 112019023014 A2 BR112019023014 A2 BR 112019023014A2 BR 112019023014 A BR112019023014 A BR 112019023014A BR 112019023014 A2 BR112019023014 A2 BR 112019023014A2
- Authority
- BR
- Brazil
- Prior art keywords
- lamp constructs
- improved lamp
- constructs
- cancer antigens
- improved
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762500053P | 2017-05-02 | 2017-05-02 | |
| US62/500,053 | 2017-05-02 | ||
| US201762561760P | 2017-09-22 | 2017-09-22 | |
| US62/561,760 | 2017-09-22 | ||
| PCT/US2018/030725 WO2018204534A1 (en) | 2017-05-02 | 2018-05-02 | Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023014A2 true BR112019023014A2 (pt) | 2020-05-19 |
Family
ID=62528827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023014-9A BR112019023014A2 (pt) | 2017-05-02 | 2018-05-02 | constructos de lamp aperfeiçoados compreendendo antígenos de câncer |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12358962B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3618854A1 (cg-RX-API-DMAC10.html) |
| JP (3) | JP7222915B2 (cg-RX-API-DMAC10.html) |
| KR (2) | KR20240027895A (cg-RX-API-DMAC10.html) |
| CN (1) | CN110913892A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2018263923B9 (cg-RX-API-DMAC10.html) |
| BR (1) | BR112019023014A2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3061950A1 (cg-RX-API-DMAC10.html) |
| IL (2) | IL297073B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018204534A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021523185A (ja) * | 2018-05-15 | 2021-09-02 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | アレルゲンを含む改善されたlamp構築物 |
| KR20220083773A (ko) | 2019-10-18 | 2022-06-20 | 이뮤노믹 쎄라퓨틱스, 인크. | 암 항원을 포함하는 개선된 lamp 구축물 |
| EP4082560B1 (en) * | 2021-04-27 | 2025-02-26 | Academia Sinica | Prap1 polypeptide for use in treating hypertriglyceridemia |
| CA3247515A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237115A (en) | 1977-11-23 | 1980-12-02 | Bactex, Inc. | Method of immunization against enterotoxogenic infection by Escherichia coli |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4397844A (en) | 1978-02-24 | 1983-08-09 | Ciba-Geigy Corporation | Antigen derivatives and processes for their preparation |
| GB2026340B (en) | 1978-07-03 | 1982-12-22 | Ash P | Stabilising microvesicles |
| US4681762A (en) | 1979-05-23 | 1987-07-21 | Research Corporation | Genetically attenuated bacterial vaccines with multiple mutations of the same phenotype |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4769330A (en) | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US4593002A (en) | 1982-01-11 | 1986-06-03 | Salk Institute Biotechnology/Industrial Associates, Inc. | Viruses with recombinant surface proteins |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4592002A (en) | 1983-12-13 | 1986-05-27 | Honeywell Inc. | Method of digital temperature compensation and a digital data handling system utilizing the same |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| ZA858044B (en) | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| GB2183662B (en) | 1985-04-01 | 1989-01-25 | Celltech Ltd | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| FR2583429B1 (fr) | 1985-06-18 | 1989-11-03 | Transgene Sa | Vecteur d'expression de l'interferon u dans les cellules de mammifere, procede pour sa mise en oeuvre et produit obtenu et composition pharmaceutique contenant l'interferon u |
| DE3689123T2 (de) | 1985-11-01 | 1994-03-03 | Xoma Corp | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| DE3642912A1 (de) | 1986-12-16 | 1988-06-30 | Leybold Ag | Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5744166A (en) | 1989-02-25 | 1998-04-28 | Danbiosyst Uk Limited | Drug delivery compositions |
| EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5676954A (en) | 1989-11-03 | 1997-10-14 | Vanderbilt University | Method of in vivo delivery of functioning foreign genes |
| US5100587A (en) | 1989-11-13 | 1992-03-31 | The United States Of America As Represented By The Department Of Energy | Solid-state radioluminescent zeolite-containing composition and light sources |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| DK0553244T4 (da) | 1990-10-05 | 2005-08-01 | Celldex Therapeutics Inc | Målrettet immunostimulering med bispecifikke reagenser |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| US5179993A (en) | 1991-03-26 | 1993-01-19 | Hughes Aircraft Company | Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid |
| EP0582595A1 (en) | 1991-04-26 | 1994-02-16 | Surface Active Limited | Novel antibodies, and methods for their use |
| SE503225C2 (sv) | 1991-10-30 | 1996-04-22 | Leif Lindholm Konsult Ab | Virus-antikroppskomplex för införing av virus i mammalieceller |
| US5661133B1 (en) | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
| PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| ATE182651T1 (de) | 1992-06-09 | 1999-08-15 | Hoppe Ag | Riegel und türschloss |
| GB9213033D0 (en) | 1992-06-19 | 1992-08-05 | British Telecomm | Method of controlling a telecommunications network |
| US5747323A (en) | 1992-12-31 | 1998-05-05 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Retroviral vectors comprising a VL30-derived psi region |
| US5633234A (en) | 1993-01-22 | 1997-05-27 | The Johns Hopkins University | Lysosomal targeting of immunogens |
| FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| FR2707091B1 (fr) | 1993-06-30 | 1997-04-04 | Cohen Haguenauer Odile | Vecteur rétroviral pour le transfert et l'expression de gènes dans des cellules eucaryotes. |
| US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| MX9504664A (es) | 1994-03-07 | 1997-05-31 | Dow Chemical Co | Conjugados de dendrimeros bioactivos y/o dirigidos. |
| JPH10501963A (ja) | 1994-04-15 | 1998-02-24 | ターゲテッド ジェネティクス コーポレイション | 遺伝子送達融合タンパク質 |
| FR2719316B1 (fr) | 1994-04-28 | 1996-05-31 | Idm | Nouveaux complexes d'acide nucléique et de polymère, leur procédé de préparation et leur utilisation pour la transfection de cellules. |
| WO1996000295A1 (en) | 1994-06-27 | 1996-01-04 | The Johns Hopkins University | Targeted gene delivery system |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| EP1658772A3 (en) | 1995-01-17 | 2007-01-17 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| FR2737222B1 (fr) | 1995-07-24 | 1997-10-17 | Transgene Sa | Nouveaux vecteurs viraux et lignee pour la therapie genique |
| WO1997035996A1 (en) | 1996-03-25 | 1997-10-02 | Transgene S.A. | Packaging cell line based on human 293 cells |
| JP2000514290A (ja) | 1996-07-01 | 2000-10-31 | ローヌ―プーラン・ロレ・エス・アー | 組換えアデノウイルスの製造方法 |
| AU3739697A (en) | 1996-07-09 | 1998-02-02 | Johns Hopkins University, The | Gene delivery system |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| EP1972194A1 (en) | 1996-12-03 | 2008-09-24 | Amgen Fremont Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
| IL130198A (en) | 1996-12-13 | 2005-09-25 | Schering Corp | Methods for purifying viruses |
| FR2759382A1 (fr) | 1997-02-10 | 1998-08-14 | Transgene Sa | Nouveaux composes et compositions les contenant utilisables pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique |
| FR2760193B1 (fr) | 1997-02-28 | 1999-05-28 | Transgene Sa | Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules |
| FR2763958A1 (fr) | 1997-05-29 | 1998-12-04 | Transgene Sa | Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique |
| JP2002506436A (ja) | 1997-06-13 | 2002-02-26 | ザ ジョンズ ホプキンス ユニバーシティー | 治療用ナノスフェア |
| AU707186B2 (en) | 1997-07-01 | 1999-07-01 | Transgene S.A. | Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy |
| ES2180258T3 (es) | 1998-07-07 | 2003-02-01 | Transgene Sa | Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes. |
| CA2364934C (fr) | 1999-02-22 | 2011-10-18 | Transgene S.A. | Procede d'obtention d'une preparation virale purifiee |
| US6511832B1 (en) | 1999-10-06 | 2003-01-28 | Texas A&M University System | In vitro synthesis of capped and polyadenylated mRNAs using baculovirus RNA polymerase |
| EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
| ES2404689T3 (es) | 2001-04-05 | 2013-05-28 | The Johns Hopkins University | Vacunas quiméricas que comprenden el dominio lumenal de LAMP-1 o LAMP-2 |
| EP1795599A1 (en) | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
| US20070269457A1 (en) | 2006-05-16 | 2007-11-22 | The Buck Institute For Age Research | Immunotherapeutic compositions and methods |
| US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
| EP2161279A1 (en) | 2008-08-29 | 2010-03-10 | Centre National de la Recherche Scientifique | Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies |
| CN107617110A (zh) | 2009-08-26 | 2018-01-23 | 西莱克塔生物科技公司 | 诱导t细胞辅助的组合物 |
| WO2011046996A2 (en) | 2009-10-13 | 2011-04-21 | The Johns Hopkins University | Consensus sequence for influenza a virus |
| RU2623161C2 (ru) | 2011-04-15 | 2017-06-22 | Компуджен Лтд. | Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака |
| US20160185831A1 (en) | 2011-06-14 | 2016-06-30 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of allergies |
| PL2861240T3 (pl) | 2012-06-15 | 2021-07-05 | Immunomic Therapeutics, Inc. | Kwasy nukleinowe do leczenia alergii |
| EP3157558A2 (en) | 2014-06-23 | 2017-04-26 | Immunomic Therapeutics, Inc. | Nucleic acids for treatment of peanut allergies |
| EP3328394A4 (en) | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | CONCATEMEE peptide epitope RNAs |
| EP3612556B8 (en) * | 2017-04-22 | 2024-11-20 | Immunomic Therapeutics, Inc. | Improved lamp constructs |
-
2018
- 2018-05-02 WO PCT/US2018/030725 patent/WO2018204534A1/en not_active Ceased
- 2018-05-02 BR BR112019023014-9A patent/BR112019023014A2/pt active Search and Examination
- 2018-05-02 CN CN201880029699.0A patent/CN110913892A/zh active Pending
- 2018-05-02 KR KR1020247006135A patent/KR20240027895A/ko active Pending
- 2018-05-02 US US16/610,133 patent/US12358962B2/en active Active
- 2018-05-02 IL IL297073A patent/IL297073B2/en unknown
- 2018-05-02 IL IL270271A patent/IL270271B2/en unknown
- 2018-05-02 AU AU2018263923A patent/AU2018263923B9/en active Active
- 2018-05-02 CA CA3061950A patent/CA3061950A1/en active Pending
- 2018-05-02 EP EP18729224.8A patent/EP3618854A1/en active Pending
- 2018-05-02 JP JP2019560156A patent/JP7222915B2/ja active Active
- 2018-05-02 KR KR1020197035028A patent/KR20200016224A/ko not_active Ceased
-
2022
- 2022-12-27 JP JP2022209238A patent/JP7407902B2/ja active Active
-
2023
- 2023-12-19 JP JP2023213451A patent/JP7657282B2/ja active Active
-
2025
- 2025-06-06 US US19/230,626 patent/US20250333458A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200016224A (ko) | 2020-02-14 |
| WO2018204534A1 (en) | 2018-11-08 |
| IL270271B2 (en) | 2023-03-01 |
| JP7657282B2 (ja) | 2025-04-04 |
| JP7407902B2 (ja) | 2024-01-04 |
| AU2018263923B2 (en) | 2024-08-22 |
| CN110913892A (zh) | 2020-03-24 |
| US20200087365A1 (en) | 2020-03-19 |
| JP2024037951A (ja) | 2024-03-19 |
| US20250333458A1 (en) | 2025-10-30 |
| JP2023036863A (ja) | 2023-03-14 |
| AU2018263923A1 (en) | 2019-10-31 |
| KR20240027895A (ko) | 2024-03-04 |
| IL297073B2 (en) | 2023-12-01 |
| IL297073B1 (en) | 2023-08-01 |
| JP2020518613A (ja) | 2020-06-25 |
| IL297073A (en) | 2022-12-01 |
| CA3061950A1 (en) | 2018-11-08 |
| IL270271A (cg-RX-API-DMAC10.html) | 2019-12-31 |
| IL270271B (en) | 2022-11-01 |
| JP7222915B2 (ja) | 2023-02-15 |
| AU2018263923B9 (en) | 2024-09-19 |
| EP3618854A1 (en) | 2020-03-11 |
| US12358962B2 (en) | 2025-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002094A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. (divisional solicitud 201803153) | |
| CY1124896T1 (el) | Αντισωματα κατα της αλφα-συνουκλεïνης και χρησεις αυτων | |
| CR20170138A (es) | Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer | |
| CL2019000146A1 (es) | Anticuerpos anti - gprc5d, moléculas de unión de antigeno bioespecificos que enlazan gprc5d y cd3, y usos relacionados. | |
| SV2018005634A (es) | Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y usos de estos | |
| PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| CU20170014A7 (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
| UY36302A (es) | Proteína de unión a antígenos, bi-específicos del receptor anti-cgrp/receptor pac1 y usos de las mismas | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| BR112018074453A2 (pt) | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral | |
| BR112016018288A2 (pt) | proteínas de fusão de interleucina 2 e uso das mesmas | |
| MX2021008334A (es) | Ligadores que modulan la estabilidad para usar con conjugados anticuerpo-farmaco. | |
| CU20160101A7 (es) | Inmunoglobulina con fab en tándem | |
| CL2015002246A1 (es) | Conjugados de anticuerpos drogas. | |
| BR112017008696A2 (pt) | métodos e composições para células exterminadoras naturais | |
| MX2017005258A (es) | Terapia combinada para tratamiento de enfermedad. | |
| BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
| UY35399A (es) | Conjugados de fármacos con anticuerpos | |
| MX389560B (es) | Enfoque de inmunoterapias de combinación para el tratamiento del cancer. | |
| PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
| JO3537B1 (ar) | أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة | |
| MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
| EP4512477A3 (en) | Improved lamp constructs | |
| MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |